19 November 2017
News and Views
Links and Services
The latest issue of Alimentary Pharmacology & Therapeutics identify predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease.
Adalimumab is a fully human monoclonal antibody targeting tumour necrosis factor with proven effi
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors